Skip to main content

UM School of Medicine's Department of Radiation Oncology Announces that Preeminent Scientist, Dr. Zeljko Vujaskovic, will Transition to New Role in the Department

December 07, 2021


Dr. Vujaskovic has made major contributions to research in hyperthermia and radiation countermeasures; Will work with faculty and staff on major targeted research projects

Zeljko Vujaskovic, MD, PhDUniversity of Maryland School of Medicine (UMSOM) Radiation Oncology Department Chair William F. Regine, MD, FACR, FACRO, announced today that Zeljko Vujaskovic, MD, PhD, Professor and Vice Chair for Research in the Department of Radiation Oncology, will transition from his current faculty position to a new role in the Department, effective December 3, 2021.

In his new role, he will work closely with Department of Radiation Oncology faculty and staff, focusing specifically on hyperthermia and FLASH-based research projects, industry collaboration opportunities, extramural funding efforts, and continued countermeasure activities. A national search has been underway to recruit an experienced physician/scientist radiation oncologist as the department’s new Vice Chair for Research.

Dr. Vujaskovic is an internationally recognized NIH-funded radiation oncologist/biologist whose more than 30-year career has been defined by transdisciplinary research. His work bridges the gap between basic science and clinic research, with the ultimate goal of improving outcomes and long-term quality of life for cancer patients. He joined the UMSOM in 2012 from his previous position at Duke University Medical Center.

William F. Regine, MD, FACR, FACRO“Dr. Vujaskovic’s clinical and research prowess in the areas of hyperthermia and radiation countermeasures/protectors/sensitizers has brought the UMSOM Department of Radiation Oncology to unparalleled levels of success and national recognition,” said Dr. Regine, who is the Isadore & Fannie Schneider Foxman Chair, Department of Radiation Oncology. “We are fortunate that he leaves us with a wonderful legacy research infrastructure and leadership team in place, and that he will now focus on these targeted areas that have significant impact.”

At UMSOM, Dr. Vujaskovic established the new Division of Translational Radiation Sciences (DTRS) within the Department of Radiation Oncology, while continuing to focus on hyperthermia by creating one of the largest clinical thermal therapy services in the country. His division’s research has been continuously supported by NIH, the Biomedical Advanced Research and Development Authority, and other federal agencies, as well as industry sponsors. Most recently, he received a five-year, $12.2 million U19 award from the National Institute of Allergy and Infectious Diseases (NIAID) to establish a NIAID Center for Medical Countermeasures Against Radiation at the UMSOM.

Isabel Lauren Jackson, PhDIsabel Lauren Jackson, PhD, Marlene and Stewart Greenebaum Associate Professor of Radiation Oncology, who co-founded DTRS with Dr. Vujaskovic, became DTRS director earlier in 2021.

“Dr. Vujaskovic is a visionary leader and physician-scientist whose career has been dedicated to bringing new therapeutics to clinical trial to increase the likelihood of cancer cure and improve the quality of life of cancer survivors,” Dr. Jackson said. “His unique ability to bring people together from across academia, industry, and federal agencies has advanced our understanding of how tumors and healthy tissue respond to radiation therapy and formidably impacted patient care – particularly those with difficult to treat disease.  We look forward to having him continue in this new targeted role in the Department.”

UMSOM Dean E. Albert Reece, MD, PhD, MBA, who is Executive Vice President for Medical Affairs and the John Z. and Akiko K. Bowers Distinguished Professor, commented: “Dr. Vujaskovic has been one of our most distinguished and prolific scientists.  We are privileged to have recruited him to the UMSOM, where he has had an enormous impact in the Department of Radiation Oncology, and has served as a tremendous mentor and faculty leader over the past 9 years. We are grateful and delighted that he will continue to serve a valuable role in the department in the future.”

About the University of Maryland School of Medicine

Now in its third century, the University of Maryland School of Medicine was chartered in 1807 as the first public medical school in the United States. It continues today as one of the fastest growing, top-tier biomedical research enterprises in the world -- with 46 academic departments, centers, institutes, and programs, and a faculty of more than 3,000 physicians, scientists, and allied health professionals, including members of the National Academy of Medicine and the National Academy of Sciences, and a distinguished two-time winner of the Albert E. Lasker Award in Medical Research.  With an operating budget of more than $1.2 billion, the School of Medicine works closely in partnership with the University of Maryland Medical Center and Medical System to provide research-intensive, academic and clinically based care for nearly 2 million patients each year. The School of Medicine has nearly $600 million in extramural funding, with most of its academic departments highly ranked among all medical schools in the nation in research funding.  As one of the seven professional schools that make up the University of Maryland, Baltimore campus, the School of Medicine has a total population of nearly 9,000 faculty and staff, including 2,500 students, trainees, residents, and fellows. The combined School of Medicine and Medical System (“University of Maryland Medicine”) has an annual budget of over $6 billion and an economic impact of nearly $20 billion on the state and local community. The School of Medicine, which ranks as the 8th highest among public medical schools in research productivity (according to the Association of American Medical Colleges profile) is an innovator in translational medicine, with 606 active patents and 52 start-up companies.  In the latest U.S. News & World Report ranking of the Best Medical Schools, published in 2021, the UM School of Medicine is ranked #9 among the 92 public medical schools in the U.S., and in the top 15 percent (#27) of all 192 public and private U.S. medical schools.  The School of Medicine works locally, nationally, and globally, with research and treatment facilities in 36 countries around the world. Visit medschool.umaryland.edu

Contact

Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559

Contact Media Relations
(410) 706-5260

Related stories

    Monday, May 08, 2023

    Patients with Advanced Prostate Cancer May Benefit from Focused Radiation Therapy that Targets Metastases

    University of Maryland School of Medicine (UMSOM) faculty recently launched a new clinical trial to test a targeted form of highly-focused radiation therapy in patients with advanced prostate cancer that has spread to distant sites in the body. The study aims to determine whether the innovative approach – which uses highly-focused radiation beams to carefully target small metastases – can extend survival in these patients.


    Thursday, March 09, 2023

    Leading Physician-Scientist Dr. William F. Regine Named Senior Associate Dean for Clinical Affairs at UM School of Medicine and President of UM Faculty Physicians, Inc.

    University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD announced today that William F. Regine, MD, FACR, FASTRO, FACRO has been appointed to the executive role of Senior Associate Dean for Clinical Affairs at the University of Maryland School of Medicine (SOM), effective immediately.


    Tuesday, August 24, 2021

    Three UMSOM Faculty Members Recognized as 2021 Maryland Daily Record Health Care Heroes

    The Maryland Daily Record has honored three leading faculty members at the University of Maryland School of Medicine (UMSOM) with its 2021 Health Care Heroes Awards. The award recognizes those who have provided exceptional service and made significant impacts on the quality of health care in the State of Maryland this year. An outside panel of health care experts selected the winners.


    Friday, July 26, 2019

    Dr. Amit Sawant Named Chief of Division of Medical Physics in Radiation Oncology

    William F. Regine, MD, FACRO, the Isadore and Fannie Schneider Foxman Chair and Professor of Radiation Oncology at the University of Maryland School of Medicine (UMSOM), and Dean E. Albert Reece, MD, PhD, MBA, announced today that Amit Sawant, PhD, MS, Associate Professor of Radiation Oncology, has been named Chief of Medical Physics in the Department of Radiation Oncology.


    Monday, October 08, 2018

    High-Precision Proton Therapy More Effective in Treating Certain Cancers When Combined with Thermal Therapy

    The Maryland Proton Treatment Center (MPTC) is now offering deep-tissue external thermal therapy in combination with high-precision proton-beam radiotherapy as a potential way to boost survival chances for certain cancer patients. MPTC is the only center in the world to offer these two treatments at the same facility, an advantage to patients because these therapies are typically given within an hour of each other.


    Monday, September 24, 2018

    University of Maryland School of Medicine Researchers to Present Original Research at Key Radiation Conference

    The University of Maryland School of Medicine (UMSOM) announced that the Division of Translational Radiation Science (DTRS) will participate in the annual meeting of the Radiation Research Society (RRS) on September 23-26, 2018, in Chicago.


    Wednesday, October 18, 2017

    University of Maryland School of Medicine Scientists Set to Begin Critical Radiation Countermeasures Research

    University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that UM SOM researchers have been awarded a contract worth up to $9.7 million over three years, from the U.S. Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services to study new ways to treat radiation-induced bleeding disorders. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services.


    Wednesday, April 13, 2016

    Leading Physician-Scientist at University of Maryland School of Medicine Receives Award for Innovative Work in Thermal Treatment for Cancer

    Zeljko Vujaskovic, MD, PhD, an internationally recognized physician scientist and Professor of Radiation Oncology at the University of Maryland School of Medicine (UM SOM), will receive the 2016 J. Eugene Robinson Award at the annual Society for Thermal Medicine Meeting in New Orleans, held April 11 to 15. Dr. Vujaskovic, who is also Director of the Division of Translational Radiation Sciences in the UM SOM Department of Radiation Oncology, and Director of the Maryland Proton Alliance at UM SOM, will receive the award in recognition of his contributions to hyperthermic oncology, the use of heat to treat cancer. At the event, Dr. Vujaskovic will also present a lecture on the reemerging role of thermal therapy in cancer treatment.


    Friday, January 15, 2016

    UM SOM to Participate in Expanded Medical Countermeasures Research Project

    University of Maryland School of Medicine (UM SOM) Department of Radiation Oncology Chair and Professor William F. Regine, MD, FACR, FACRO, and UM SOM Dean E. Albert Reece, MD, PhD, MBA, announced today that researchers at the UM SOM have been selected as key contractors by the Biomedical Advanced Research and Development Authority (BARDA), for its Radiation Nuclear Animal Model Development program. BARDA is part of the Office of the Secretary for Preparedness and Response in the U.S. Department of Health and Human Services (DHHS).